1898 — Felix Hoffmann Filed the Substance Patent for 'Acetyl Salicylic Acid' US644077A. Germany Refused the Patent; the U.S. Granted It in 1900. Reading the Origin of Branded Pharmaceuticals from Primary Sources

About excavation memos: "Excavation memos" in this series record candidate summaries at the stage where the primary-source URL has been confirmed. Full-text reading and verbatim verification of all claims have not been performed. Only confirmed facts are recorded; speculation is explicitly marked.

Why dig

Aspirin (acetyl salicylic acid, ASA) is one of the world's most-recognized pharmaceuticals, with over 100 billion tablets estimated to be consumed annually. Since the 1980s, low-dose (100mg / 81mg) aspirin has been re-evaluated as the standard antiplatelet therapy for cardiovascular disease prevention and occupies the center of the OTC (over-the-counter) market.

The textbook narrative widely circulates the story "In 1897, Felix Hoffmann synthesized acetyl salicylic acid to treat his father's rheumatism, and Bayer commercialized it as Aspirin." But the patent's inventor dispute (in 1949, former colleague Arthur Eichengrün claimed "I directed the actual synthesis; Hoffmann only executed the experiment"), the German patent rejection, and the post-WWI U.S. asset seizure are rarely referenced in general technology discourse.

The DB row FH-003 in ~/ai-archaeology/db/candidates.tsv lists "Felix Hoffmann," "Farbenfabriken vormals Friedrich Bayer (now Bayer AG)," and "1897 synthesis, Eichengrün dispute exists" — consistent with the primary sources confirmed on Google Patents:

• Patent number US644077A: Title "Acetyl salicylic acid," inventor "Felix Hoffmann" (sole), assignee "Farbenfabriken of Elberfeld Co" (Bayer's old U.S. corporate name), filed 1898-08-01, granted 1900-02-27, expired 1917-02-27 (17 years from grant). Claim 1 encloses acetyl salicylic acid itself as a "new article of manufacture" — a substance patent.

While Day 11 surfaced consecutive DB inventor errors in PH-007 (captopril) and PH-005 (propranolol), FH-003 is the rare case where the DB description matches the primary source. As feedback_db_meta_verify_primary indicates, while the DB is highly likely to contain arc-quotation errors, cases of agreement also occur, like this one.

Patent basic information

• Patent number: US644077A
• Title: Acetyl salicylic acid
• U.S. filing date: August 1, 1898
• U.S. grant date: February 27, 1900
• Inventor: Felix Hoffmann (sole, matches DB description)
• Original Assignee: Farbenfabriken of Elberfeld Co. (U.S. corporate name; German parent was Farbenfabriken vorm. Friedr. Bayer & Co., later Bayer AG)
• Current Assignee: Farbenfabriken of Elberfeld Co.
• U.S. expiration: February 27, 1917 (17 years from grant)
• Primary source: Google Patents (URL confirmed; title, Claim 1 summary, sole inventor, filing/grant dates, assignee — all retrieved)

Core (Google Patents retrieved information)

US644077A Claim 1 (summary) reads:

The herein-described new article of manufacture, acetyl salicylic acid, having the formula [chemical structure], being a white crystalline substance which crystallizes in needles from dry chloroform, dissolves easily in benzene and alcohol but only slightly in cold water, melts at about 135 degrees Celsius, and decomposes upon being boiled with water into acetic acid and salicylic acid.

The skeleton defines acetyl salicylic acid by five physicochemical properties: (1) classification as "new article of manufacture," (2) chemical formula C9H8O4 (described as a structural formula in the specification), (3) white needle crystals from chloroform, (4) soluble in benzene/alcohol, slightly soluble in cold water, melting point ~135°C, (5) hydrolysis to acetic acid and salicylic acid in hot water. As a substance patent, it encloses acetyl salicylic acid itself, with the manufacturing method (acetylation using acetic anhydride) also recorded in the specification. Claim 1 asserts the substance itself.

Important points in the specification:

• 1897 synthesis record: The specification records that Hoffmann reacted salicylic acid with acetic anhydride in 1897 to synthesize acetyl salicylic acid. Higher-purity crystals were obtained than via the acetyl chloride method dominant at the time, providing one basis for novelty.
• Differentiation from existing technology: The opening of the specification states "the prior acetyl chloride method did not yield pure acetyl salicylic acid," distinguishing Hoffmann's acetic-anhydride synthesis process.
• Indications: The specification limits descriptions of specific medical indications. From 1899, Bayer marketed it as a pharmaceutical under the "Aspirin" trademark, spreading uses for rheumatic fever, fever reduction, and analgesia.

In Germany, the patent was rejected for "lack of novelty." With Charles Frédéric Gerhardt's first reported synthesis of acetyl salicylic acid in 1853 (impurities prevented commercialization) and Karl Johann Kraut's improved synthesis in 1869 as prior art, the German Patent Office judged Hoffmann's synthesis to be "an improvement on prior art." The U.S. and U.K. patent offices, by contrast, recognized Hoffmann's acetic-anhydride method as a "new article of manufacture" and granted substance patents.

Modern correspondence (includes speculation)

A note on how to read this correspondence table.

Row 1 is strained. The 1898 patent's acetyl salicylic acid and the 1980s-onward low-dose antiplatelet therapy are the same substance, but (a) use (antipyretic/analgesic vs. cardiovascular prevention), (b) dose (500-1000mg vs. 81-100mg), (c) understanding of the mechanism (unknown in the late 19th century; modern view is irreversible cyclooxygenase-1 inhibition suppressing thromboxane A2), and (d) target patients (general pain vs. cardiovascular risk patients) differ fundamentally. Connecting the 1898 patent directly to modern antiplatelet therapy is emotionally easy to grasp but causally weak in patent-history terms. Claim 1 asserts the substance itself, but modern usage was established along a different lineage after John Vane's 1971 elucidation of cyclooxygenase mechanism (later 1982 Nobel Prize) and the 1988 Steering Committee of the Physicians' Health Study Research Group's myocardial infarction prevention RCT results.

Row 2 is identical. In 1899, Bayer launched "Aspirin" as a trademark, establishing the concept of branded drugs (a brand name attached to a chemical substance name, acetyl salicylic acid). This is the direct predecessor of modern Pfizer / J&J / Bayer / Roche brand-name drug strategies, with the trademark + substance-patent combination enclosure model continuing.

Row 3 is identical. After the 1917 U.S. patent expiration, Sterling Products Co. (the U.S. company that purchased Bayer's U.S. assets in December 1918) continued to sell "Bayer Aspirin," and generic/OTC aspirin also expanded into the market. The "patent expiration → generic/OTC expansion" model is inherited as a standard structure of the modern pharmaceutical market.

Row 4 is similar. In December 1918, under the U.S. Trading with the Enemy Act (enacted 1917), Bayer's U.S. assets (patents, trademarks, factories) were seized by the Alien Property Custodian and sold to Sterling Products Co. for $5,310,000. The "Bayer" and "Aspirin" trademarks in the U.S. were held by the U.S. side (Sterling → SmithKline Beecham → eventually Bayer AG buyback) until 1994. Referenced today as a wartime intellectual-property seizure case (WWII I.G. Farben dissolution, recent Russian corporate asset freezes, etc.).

Row 5 is metaphorical. During the 1918 Spanish flu pandemic, mass dosing of aspirin was recommended in the U.S. (some medical manuals recommended over 30g daily), and overdose-induced pulmonary edema and gastrointestinal bleeding may have constituted part of the death toll (Karen Starko 2009 Clinical Infectious Diseases paper, etc.). It overlaps with concerns over non-expert misuse during the COVID-19 pandemic (hydroxychloroquine, ivermectin, vitamin D, etc.) at the level of "pandemic × pharmaceutical social concern," but with different substances and eras, so it stays at the metaphorical level.

Row 6 is similar. In 1949, Arthur Eichengrün (former Bayer chemist, Jewish, expelled from the company under the Nazi regime in 1938, imprisoned at Theresienstadt concentration camp in 1943, survived in 1945) claimed "I directed the actual synthesis of acetyl salicylic acid; Hoffmann only executed the experiment." Bayer maintains the Hoffmann sole-invention narrative, but in 2000, Walter Sneader (Strathclyde University) published a paper supporting Eichengrün's claim in BMJ ("The discovery of aspirin: a reappraisal" BMJ 321:1591-1594). Eichengrün's contribution may have been deleted from documents under the Nazi regime from 1938 onward, and Sneader's paper is discussed in the narrative of "historical erasure of Jewish scientists' contributions." It overlaps with modern AI drug discovery / large-scale research co-author / inventor recognition disputes (who contributed, whose names are recorded) at the level of problem awareness.

Row 7 is identical. The form of "enclosing the compound itself with a substance patent" is the standard for modern pharmaceutical substance patents, with US644077A as one early example. The multi-layer structure of substance patent + use patent + formulation patent + crystal-form patent is also followed today.

Row 8 is identical. Cases of "the same invention granted in one country and rejected in another" still frequently occur today, with judgment differences between the European Patent Office, U.S. Patent and Trademark Office, and Japan Patent Office a major issue in patent strategy. US644077A is an early example from 100 years ago, where the German Patent Office's "known prior art" judgment and the U.S. Patent Office's "new article of manufacture" judgment coexisted.

Why is it worth digging? (speculation)

Reason 1: Verification of the "Hoffmann synthesized for his father's rheumatism" story

Textbooks and general-audience books widely circulate the story "In 1897, Felix Hoffmann synthesized acetyl salicylic acid to treat his father (a rheumatism patient)." But this story may not be explicitly recorded in Bayer internal records before 1949, and Sneader's 2000 BMJ paper criticizes the Hoffmann father-treatment motive as "a narrative added afterward to erase Eichengrün's contribution." Verification of primary sources (Bayer internal research records, Hoffmann handwritten notebook, official documents before 1949) is needed, but reference to the Bayer Archive (Leverkusen) is not implemented within this article's scope.

Reason 2: Historical case of WWI and pharmaceutical patents

The December 1918 U.S. Trading with the Enemy Act seizure of Bayer's U.S. assets is referenced today as an early example of wartime intellectual-property policy. The fact that the "Bayer" and "Aspirin" trademarks remained on the U.S. side until 1994 is important as a historical case of intellectual property crossing national borders due to war and politics. Reading it alongside recent cases like the Russian corporate asset freezes (2022-) makes the continuity of wartime intellectual-property policy visible.

Reason 3: 120-year continuing brand × substance-patent structure

US644077A expired in the U.S. in 1917, but Bayer's "Aspirin" brand is still sold worldwide today — a rare example of brand value being maintained even after substance-patent expiration. This structure is supported by (a) trademark continuation via the 1899 trademark registration, (b) advantages in manufacturing know-how and quality control, and (c) consumer brand recognition — references for modern pharmaceutical marketing strategies. Substance patents = limited rights of 17-20 years, but brands can continue for over 100 years.

Pitfalls

Pitfall 1: "Hoffmann is the sole inventor" is correct in patent terms but historically debated

US644077A's inventor field lists Felix Hoffmann alone, an established fact in patent history. But following the 1949 Eichengrün dispute and Sneader's 2000 BMJ paper, the academic theory has been raised that "Eichengrün directed the actual synthetic innovations and Hoffmann was the experimental executor." Bayer maintains the Hoffmann sole theory, but the possibility cannot be denied that Eichengrün's contribution as a Jewish scientist was deleted from documents under the Nazi regime (1933-1945). It must be read as a case where "patent inventor ≠ historical inventor."

Pitfall 2: "German patent rejection = German technical judgment was wrong" is an oversimplification

The German Patent Office judged Hoffmann's synthesis to be "an improvement on prior art" because of preceding synthesis papers by Gerhardt in 1853 and Kraut in 1869. The U.S. Patent Office recognized Hoffmann's acetic-anhydride method as a "new article of manufacture," but this is a difference in patent-system judgment standards — evaluating it as "Germany was wrong" ignores institutional context. The 1898 inconsistency in prior-art judgments by national patent offices is a structural problem inherited by modern Western/Japanese patent prosecution judgment differences.

Pitfall 3: "Aspirin = cardiovascular prevention drug" is a 1980s-onward use

Aspirin from 1898 to the 1980s was prescribed as an antipyretic/analgesic/anti-inflammatory drug; cardiovascular prevention (antiplatelet therapy) was a use established after Vane's 1971 cyclooxygenase mechanism elucidation and the 1988 Physicians' Health Study RCT. Modern indications are split: (a) primary prevention (healthy individuals without cardiovascular risk) is not recommended (gastrointestinal bleeding risk exceeds benefit), (b) low-dose aspirin is standard for secondary prevention (history of myocardial infarction or cerebral infarction). Simplifying "aspirin is a prevention drug" goes against modern clinical guidelines.

Pitfall 4: "1918 Spanish flu mass aspirin dosing as cause of death" is a hypothesis

Karen Starko's 2009 Clinical Infectious Diseases paper hypothesized that "part of the elevated mortality of the 1918 Spanish flu was due to aspirin overdosing," but this hypothesis is under academic verification, not an established fact. The elevated mortality of the time had multiple factors: (a) virus toxicity itself, (b) secondary bacterial pneumonia, (c) wartime medical resource shortage, (d) aspirin overdosing. Emphasizing only (d) as the cause is an oversimplification.

Strictly speaking

Confirmed facts

From Google Patents: US644077A / Title "Acetyl salicylic acid" / Inventor "Felix Hoffmann" sole (matches DB description) / Original Assignee "Farbenfabriken of Elberfeld Co" (U.S. corporate name; German parent Farbenfabriken vorm. Friedr. Bayer & Co.) / Current Assignee "Farbenfabriken of Elberfeld Co" / Priority/Filing date 1898-08-01 / Grant date 1900-02-27 / Expiration 1917-02-27 (17 years from grant) / Claim 1 (summary) retrieved ("new article of manufacture, acetyl salicylic acid, [...] white crystalline substance, crystallizes in needles from dry chloroform, dissolves easily in benzene and alcohol but only slightly in cold water, melts at about 135 degrees Celsius, decomposes upon being boiled with water into acetic acid and salicylic acid") / 1899 "Aspirin" trademark launch (Bayer official records, confirmed by multiple pharma-history sources) / December 1918 Bayer U.S. asset seizure (Trading with the Enemy Act applied, confirmed by multiple legal-history sources).

Author's interpretation "100-year continuing structure of substance patent + branded pharmaceuticals," "historical continuity of wartime intellectual-property policy," and "overlap of problem awareness with modern AI drug discovery inventor disputes" are author interpretations. Details of the Eichengrün 1949 dispute and existence of Bayer internal records are not confirmed within this article's scope. Sneader's 2000 BMJ paper claim is academically debated, and "Hoffmann sole theory is incorrect" cannot be definitively concluded.

Metaphors / analogies Row 1 (1898 substance patent vs. 1980s antiplatelet therapy) is strained. Same substance but use, dose, and understanding of mechanism fundamentally different. Row 5 (1918 Spanish flu aspirin misuse vs. COVID-19 hydroxychloroquine misuse) is metaphorical. Different substances and eras, but positioned alongside as "pandemic × pharmaceutical social concern." Row 6 (Hoffmann vs. Eichengrün dispute vs. modern AI drug discovery inventor disputes) is similar. Problem awareness overlaps as a multi-contributor recognition issue.

Not confirmed Full text of US644077A Description, verbatim / Full text of Claims 2 onward / Bayer Archive (Leverkusen) Hoffmann handwritten notebooks and 1897 experimental records / Original Eichengrün 1949 dispute documents and related correspondence / Original Sneader 2000 BMJ paper (bibliographic info only confirmed) / Original Karen Starko 2009 Clinical Infectious Diseases paper (bibliographic info only confirmed) / December 1918 Bayer U.S. asset seizure Alien Property Custodian official records / Sterling Products Co. → SmithKline Beecham → Bayer AG trademark buyback (1994) contracts / Original 1971 John Vane Nature paper (cyclooxygenase mechanism elucidation) / Original 1988 Physicians' Health Study RCT paper / Original 1853 Gerhardt / 1869 Kraut precursor synthesis papers

Where this comparison breaks down US644077A is the 1898 acetyl salicylic acid substance patent, with use, dose, and understanding of mechanism fundamentally different from modern aspirin clinical use (especially low-dose antiplatelet therapy from the 1980s onward). Connecting "substance patent = modern clinical use" directly invites three specialist rebuttals: (1) cyclooxygenase mechanism was unknown in 1898; (2) doses of 500-1000mg vs. 81-100mg differ by an order of magnitude; (3) the clinical distinction between primary and secondary prevention is established in modern medicine. The Hoffmann vs. Eichengrün dispute is a historical debate from 1949 onward; while the patent-field inventor is conclusively Hoffmann alone, the historical truth is unresolved. The "Hoffmann synthesized for his father's rheumatism" story may not be confirmed in Bayer official documents before 1949, and the possibility of a backfilled narrative is pointed out (Sneader 2000). The excavation memo is limited to confirmation within Google Patents — Bayer Archive, Eichengrün-related correspondence, originals of Vane / Starko / Sneader papers, and Sterling Products related contracts are not retrieved, and this is explicitly noted.

Reference links:

• Original patent: US644077A on Google Patents
• Sneader 2000 BMJ "The discovery of aspirin: a reappraisal" (bibliographic info, original not retrieved): BMJ 321:1591-1594
• Karen Starko 2009 Clinical Infectious Diseases "Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence" (bibliographic info, original not retrieved)
• Related Excavation Note (Pharma Patents #1): Cetus PCR core patent US4683195A (1985)
• Related Excavation Note (Pharma Patents #2): Köhler & Milstein monoclonal antibody (1975 Nature) + Wistar US4172124A
• Related Excavation Note (Pharma Patents #3): Squibb Ondetti & Cushman ACE inhibitor (captopril) two-series patents
• Related Excavation Memo #1 (Food/Health Patents): Birdseye instant freezing US1773079A (1926 priority)
• Related Excavation Memo #2 (Food/Health Patents): Spencer microwave oven US2495429A (filed 1945)
• Related Excavation Memo #3 (Pharma Patents): ICI propranolol US3337628A + derivative US3408387A (1962-1968)